Clinical trials: Optical Neuritis
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory disease of the central nervous system characterized by relapsing optic neuritis and longitudinal extensive transverse myelitis.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica, Devic's Disease
- Trial name
- NCT03062579
- Testing
- Tocilizumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fu-Dong Shi
Neuromyelitis Optica Spectrum Disorders
Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients
The present research is an observational clinical study. The project aims to investigate astrocytic damage, assessed through biological findings such as an increase in GFAP level and/or MRI water index, in patients with NMOSD and…
- Trial name
- NCT07526298
- Testing
- MRI, Immunological Factors
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Neuromyelitis Optica Spectrum Disorders
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
- Trial name
- NCT06413654
- Testing
- B001
- Where
- 51 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Optic Neuritis, Multiple Sclerosis
Visual Reconstitution Therapy After Optic Neuritis
Incomplete remission after an optic neuritis attack is not uncommon. Visual reconstitution therapy is a software-based approach that has been shown to substantially improve residual visual field deficits in patients with pre- and…
- Trial name
- VISION (NCT01274702)
- Testing
- Visual Reconstitutions Therapy, Saccadic Eye Movement Training
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Friedemann Paul
Neuromyelitis Optica
Scrambler Trial for Pain in NMOSD
A novel technology called Scrambler Therapy is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of C fibers with the intent of re-organizing maladaptive signaling pathways.
- Trial name
- NCT03452176
- Testing
- Scrambler
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Neuromyelitis Optica
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.
- Trial name
- NCT05356858
- Testing
- zanubrutinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple Sclerosis, Optic Nerve
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
The primary objective of the study was to evaluate the effect of Nerispirdine (50 mg or 400 mg) and placebo given orally as a single dose once a week in crossover design on latency of Visual Evoked Potentials (VEP) P100 in optic…
- Conditions
- Multiple Sclerosis, Optic Nerve, Neuritis
- Trial name
- NCT00772525
- Testing
- Nerispirdine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sanofi
Optic Neuritis, Multiple Sclerosis
Amiloride Clinical Trial In Optic Neuritis
Optic neuritis (ON) is a common event in Multiple Sclerosis (MS), and causes significant loss of nerve cells in the eye, resulting in poor vision.
- Trial name
- ACTION (NCT01802489)
- Testing
- Amiloride
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- University of Oxford
Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins…
- Trial name
- N-MOmentum LT (NCT06180278)
- Testing
- Blood tests, Inebilizumab
- Where
- 11 sites in United States, China and 5 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Central Nervous System Inflammation, MOG-IgG Associated Disease
Azathioprine in MOGAD
MOG-IgG associated disease (MOGAD) is a rare inflammatory disease of the central nervous system recently described. Initially reported as monophasic, data from incident cohorts suggests that around 50% of adult patients with…
- Trial name
- MOGwAI (NCT05349006)
- Testing
- Azathioprine
- Where
- 17 sites in France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- SONICS (NCT03942952)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
NMO Spectrum Disorder, Spasticity, Muscle
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD.
- Trial name
- SENS-NMO (NCT05974293)
- Testing
- Nabiximols
- Where
- United States
- Sponsor
- Michael, Levy M.D.,Ph.D.
Neuromyelitis Optica
Safety of Therapeutic Step-down in Neuromyelitis Optica
Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment.
- Trial name
- NMO (NCT05155644)
- Where
- France
- Volunteers
- 947 people
- Sponsor
- University Hospital, Strasbourg, France
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica Spectrum Related Disorders
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Devic's neuromyelitis optica (NMO) is rare. Epidemiological and demographic data are poor, based mainly on monocentric cohorts. Moreover, NMO might be difficult to distinguish from multiple sclerosis and begin with atypical or…
- Trial name
- NOMADMUS (NCT02850705)
- Where
- France
- Volunteers
- 1,787 people
- Sponsor
- Hospices Civils de Lyon
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a multicenter, randomized, double-blind, placebo-controlled Phase Ⅱ study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with neuromyelitis optica…
- Trial name
- NCT05551598
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 46 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Devic's Disease
Hematopoietic Stem Cell Transplant in Devic's Disease
This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system)…
- Trial name
- NCT00787722
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Northwestern University
NMO Spectrum Disorder
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD)…
- Trial name
- NCT07377305
- Testing
- 10Hz tTIS (2-4mA) Intervention
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tang-Du Hospital
Optic Neuritis
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.
- Trial name
- ACHTAR (NCT01987167)
- Testing
- ACTHAR
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Neuro-Ophthalmologic Associates, PC
Myelitis, Transverse, Neuromyelitis Optica
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
This multi-center randomized controlled trial evaluates if the addition of intravenous immunoglobulin to standard treatment of corticosteroids improves outcome in children and adults with first episode of Transverse Myelitis of…
- Trial name
- STRIVE (NCT02398994)
- Testing
- Intravenous Methylprednisolone, Intravenous Immunoglobulin
- Where
- 18 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Neuromyelitis Optica
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
The overall objective is to evaluate the tolerability/safety and preliminary efficacy of CINRYZE® (C1 esterase inhibitor [human]) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in NMO and…
- Trial name
- NCT01759602
- Testing
- C1-esterase inhibitor (Cinryze)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael Levy